KEYTRUDA 50mg powder for concentrate infusion solution medication leaflet

L01FF02 • pembrolizumab • Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors

Pembrolizumab is a monoclonal antibody used in cancer immunotherapy, including the treatment of melanoma, lung cancer, and other types of cancer. It works by blocking the PD-1 receptor, allowing the immune system to recognize and destroy tumor cells.

The medication is administered intravenously, as directed by a doctor, usually once every three or six weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.

Patients should be aware of potential side effects, such as fatigue, diarrhea, or skin reactions. It is important to inform the doctor of any unusual symptoms.

Common side effects include fatigue, diarrhea, and skin reactions. In rare cases, severe reactions such as immune-related toxicity or allergic reactions may occur. Patients should be informed of these risks before use.